HC Wainwright Reaffirms Buy Rating for DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 415.46% from the company’s current price.

Several other equities research analysts also recently issued reports on DBVT. JMP Securities raised their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research note on Wednesday. StockNews.com began coverage on shares of DBV Technologies in a report on Thursday, July 25th. They set a “hold” rating on the stock.

DBV Technologies Price Performance

Shares of DBVT opened at $0.97 on Thursday. The company has a market capitalization of $93.60 million, a PE ratio of -1.15 and a beta of 0.69. DBV Technologies has a one year low of $0.50 and a one year high of $3.70. The company’s fifty day moving average price is $0.92 and its 200 day moving average price is $1.33.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative return on equity of 66.96% and a negative net margin of 638.21%. During the same period in the prior year, the firm posted ($0.26) EPS. Analysts anticipate that DBV Technologies will post -1.22 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Cowen AND Company LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.